TIANYIN PHARMACEUTICAL ANNOUNCED ITS 250-TON JIANGCHUAN MACROLIDE FACILITY IS SCHEDULED FOR ITS MANUFACTURING TEST (TPI)

Tianyin Pharmaceutical (NYSE:TPI) announced that its 250-ton Jiangchuan Macrolide facility is scheduled for its manufacturing test runs by the end of July.The test runs prepare the production lines for the final Good Manufacturing Practice certification process by conducting a series of operations and tests under actual or simulated operating conditions to verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.

No comments:

Post a Comment

Superhit News

News Archive